Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.

Cancer Med · 2020 · PMC7666748 · PMID 32969597

Europe PMC DOI

hedged sentences

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendP = 0.08so close (0.05 < p ≤ 0.1)

In a post hoc analysis of patients in advanced stage, a significant PFS advantage was observed in patient who had received ibrutinib ( P = 0.03), who showed a trend for OS advantage ( P = 0.08).

also in 53,322 other papers

of borderline significanceno p-value reported

Factors associated with a shorter PFS in univariate analysis were represented by del(17p)/ TP53 mutations, ECOG performance status and by the presence of 2 or more comorbidities, as shown in Table 2 , whereas an intermediate/advanced stage and an IGHV ‐ unmutated status were of borderline significance.

also in 2,624 other papers

borderline significantno p-value reported

The IGHV ‐unmutated configuration was associated with a shorter PFS, that was of borderline significant probably as a consequence of the limited number of patients assessed.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.